术前5-氨基乙酰丙酸与脑肿瘤术后肝酶升高相关:回顾性队列研究
该回顾性队列研究纳入179例术前肝酶正常的脑肿瘤手术患者,发现术前使用5-氨基乙酰丙酸(5-ALA)与术后肝酶升高(PELE)独立相关(OR 2.30,95%CI 1.14-4.67,P=0.021),但严重转氨酶升高的发生率低。在5-ALA治疗患者中,术前ALT水平和BMI是PELE的显著预测因素。
要点
- 术前5-ALA使用使术后肝酶升高风险增加约2.3倍,但多为短暂性。
- 5-ALA治疗患者中严重转氨酶升高(3级)发生率仅4.2%。
- 术前ALT接近正常上限和超重患者使用5-ALA时应警惕肝酶升高。
核心结论
- 术前肝酶正常的脑肿瘤患者使用5-ALA与术后短暂性肝酶升高风险增加相关,但严重转氨酶升高发生率低。
研究设计与样本
- 回顾性队列研究,纳入179例术前肝酶正常的脑肿瘤手术患者,收集术前至术后第45天的肝酶数据。
主要发现
- 5-ALA治疗患者中4例(4.2%)出现基于CTCAE的3级转氨酶升高。
- 术前5-ALA治疗预测PELE的OR为2.30(95%CI 1.14-4.67,P=0.021)。
- 5-ALA治疗患者(n=95)中41例(43.2%)出现70次PELE,术前ALT水平(OR 1.10,95%CI 1.04-1.17,P=0.001)和BMI(OR 1.29,95%CI 1.08-1.56,P=0.006)为显著预测因素。
- 5-ALA治疗患者中术后最大ALT>40 U/L的39例患者中,POD14和POD45分别有13例和36例ALT恢复正常,仅3例在POD15-45 ALT>40 U/L且呈下降趋势。
关键数值与推荐
- PELE定义为术后肝酶升高,包括ALT、AST、ALP和总胆红素升高。
- 3级转氨酶升高依据常见不良事件评价标准(CTCAE)。
- 术前ALT水平每增加1单位,PELE风险增加10%(OR 1.10,95%CI 1.04-1.17,P=0.001)。
- BMI每增加1单位,PELE风险增加29%(OR 1.29,95%CI 1.08-1.56,P=0.006)。
临床怎么用
- 对于术前ALT处于正常高值和超重的患者,使用5-ALA时应关注术后肝酶变化。
- 5-ALA相关肝酶升高多为短暂性,严重转氨酶升高发生率低,无需过度担忧。
局限性
- 回顾性研究设计可能存在选择偏倚和信息偏倚。
- 样本量有限,仅179例患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Besides 5-aminolevulinic acid (5-ALA), liver enzyme elevation after brain tumor surgery can be caused by anesthesia and medications. In this retrospective study, we determined whether preoperative 5-ALA administration is associated with postoperative elevation of liver enzymes (PELE) in brain tumor patients and identified predictive factors for PELE in patients treated with 5-ALA. METHODS: In 179 patients undergoing brain tumor surgery with preoperative normal values of liver enzymes, laboratory data on serum alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), and total bilirubin (T.bil) levels were collected preoperatively and through postoperative day (POD) 45. RESULTS: Ninety-nine PELEs (ALT, 56; AST, 34; ALP, 5; and TB, 4) were observed in 62 (34.6%) patients. Four (4.2%) patients treated with 5-ALA showed grade 3 elevation of transaminases based on the Common Terminology Criteria for Adverse Effects. Preoperative 5-ALA treatment was predictive of PELE (odds ratio [95% confidence interval], 2.30 [1.14-4.67]; P = 0.021). In patients treated with 5-ALA (n = 95), 70 PELEs (ALT, 39; AST, 22; ALP, 5; and TB, 4) were observed in 41 (43.2%) patients and significant predictive factors for PELE were preoperative ALT level (1.10 [1.04-1.17]; P = 0.001) and body mass index (BMI, 1.29 [1.08-1.56]; P = 0.006). In patients treated with 5-ALA, 13 and 36 patients, of 39 patients whose maximum postoperative ALT levels > 40 U/L, showed the normal value of serum ALT on PODs 14 and 45, respectively. Only three patients showed ALT elevation > 40 U/L on PODs 15-45, with a downward trend. CONCLUSIONS: The use of 5-ALA for brain tumor surgery in patients with preoperative normal values of liver enzymes was associated with increased transient PELE, but a low incidence of severely elevated liver transaminases levels. When 5-ALA is administered to patients with the upper normal value of preoperative serum ALT and overweight, attention is paid to PELE.
引用
- Kim JH, Yoon HK, Lee HC, et al. Preoperative 5-aminolevulinic acid administration for brain tumor surgery is associated with an increase in postoperative liver enzymes: a retrospective cohort study. Acta Neurochir (Wien). 2019. PMID: 31473825. doi:10.1007/s00701-019-04053-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。